Alogliptin
Brand names: INCRESYNC (in combination) KAZANO (in combination) NESINA OSENI (in combination) VIPDOMET (in combination) VIPIDIA
Therapeutic Indications
Alogliptin is indicated for:
Diabetes mellitus type 2
Irrespective of gender only Adults (18 years old or older)
Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 25 mg once daily
Contraindications
Active ingredient Alogliptin is contraindicated in the following cases: